96 related articles for article (PubMed ID: 24478055)
1. Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies.
Alemán JO; Farooki A; Girotra M
Endocr Relat Cancer; 2014 Jun; 21(3):R247-59. PubMed ID: 24478055
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
Deininger MW; Manley P
Leuk Res; 2012 Mar; 36(3):253-61. PubMed ID: 21996558
[TBL] [Abstract][Full Text] [Related]
4. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Breccia M; Alimena G
Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
[TBL] [Abstract][Full Text] [Related]
5. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
6. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
7. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Rohon P; Porkka K; Mustjoki S
Eur J Haematol; 2010 Nov; 85(5):387-98. PubMed ID: 20662899
[TBL] [Abstract][Full Text] [Related]
8. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
9. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
10. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
Nasr R; Bazarbachi A
Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
[TBL] [Abstract][Full Text] [Related]
11. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Giles FJ; O'Dwyer M; Swords R
Leukemia; 2009 Oct; 23(10):1698-707. PubMed ID: 19474800
[TBL] [Abstract][Full Text] [Related]
12. New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.
le Coutre P; Schwarz M; Kim TD
Clin Cancer Res; 2010 Mar; 16(6):1771-80. PubMed ID: 20197479
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
14. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
15. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
16. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
18. Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.
Tibullo D; Barbagallo I; Giallongo C; La Cava P; Branca A; Conticello C; Stagno F; Chiarenza A; Palumbo GA; Di Raimondo F
Hematol Oncol; 2012 Mar; 30(1):27-33. PubMed ID: 21544849
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity induced by tyrosine kinase inhibitors.
Orphanos GS; Ioannidis GN; Ardavanis AG
Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
[TBL] [Abstract][Full Text] [Related]
20. The skeletal effects of the tyrosine kinase inhibitor nilotinib.
O'Sullivan S; Lin JM; Watson M; Callon K; Tong PC; Naot D; Horne A; Aati O; Porteous F; Gamble G; Cornish J; Browett P; Grey A
Bone; 2011 Aug; 49(2):281-9. PubMed ID: 21550432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]